The Results Are In: 2026 Trends in Specialty Drug Benefits Report
New insights from the 2026 Trends in Specialty Drug Benefits Report, co-sponsored by Pharmaceutical Strategies Group (PSG) and Genentech, are now available. This year’s report covers the changing priorities, challenges and strategies payers are considering to ensure access to specialty therapies while managing costs.
Learn how payers are evolving their thinking about:
Learn how payers are evolving their thinking about:
- Specialty drug rebates and alternatives
- Utilization management strategies
- PBM and specialty pharmacy arrangements
- Cell and gene therapy affordability
How will your organization respond? Get ahead and be informed with these key takeaways. Access these highlights—and more—from the 2026 Report.
Please fill out the form to download the Executive Summary and see where payers are headed next.